Posttransplant lymphoproliferative disorders in lung transplant


Journal Article (Review)

As the number of lung transplant recipients grows, so does the potential prevalence of PTLD. The recent introduction of the anti-CD20 monoclonal antibody, rituximab, into clinical practice has already improved our ability to successfully treat PTLD after lung transplant. Ongoing studies of the molecular pathogenesis of B-cell transformation by EBV will likely lead to additional novel immunologically based therapies effective in the prevention or treatment of PTLD. © 2004 Lippincott Williams & Wilkins.

Full Text

Duke Authors

Cited Authors

  • Snyder, LD; Palmer, SM

Published Date

  • January 1, 2004

Published In

Volume / Issue

  • 9 / 3

Start / End Page

  • 325 - 331

Electronic International Standard Serial Number (EISSN)

  • 1531-7013

International Standard Serial Number (ISSN)

  • 1087-2418

Digital Object Identifier (DOI)

  • 10.1097/01.mot.0000135415.90704.92

Citation Source

  • Scopus